BridgeBio Pharma Inc

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

BridgeBio Pharma Inc (BBIO) reports strong Q1 performance and pipeline progress

BridgeBio Pharma Inc (BBIO) delivered a robust performance in Q1 2025, driven by strong revenue from Attruby and positive clinical data for pipeline programs. While facing challenges related to market dynamics and competition, the company remains focused on growth opportunities through patient starts and strategic financial management.

BridgeBio Pharma Inc reports robust Q2 earnings and growth opportunities

BridgeBio Pharma Inc's Q2 2025 earnings call highlighted strong financial performance, driven by Attruby's success and revenue growth. While facing challenges in optimizing patient adds and market impact, the company remains well-positioned with a focus on innovation and data-driven strategies. Opportunities for growth through pipeline programs and strategic initiatives underscore BridgeBio's potential for future success and market expansion.

BridgeBio Pharma excels in Q3 with strong financials and pipeline success

BridgeBio Pharma's Q3 2025 Earnings Call showcased strong financial performance, successful late-stage pipeline updates, and a focus on commercial excellence. The company faces challenges in product differentiation and market positioning but has opportunities for growth through upcoming launches and market expansion.

BridgeBio Pharma excels in Q4 with strong revenue growth and strategic focus on future profitability

BridgeBio Pharma's Q4 2025 performance showcased strong revenue growth driven by successful Phase III results and robust commercial momentum of Attruby. While facing challenges in managing operating costs and transitioning to cash generation, the company's strategic strengths in pipeline development and global market focus position it for future success. Opportunities lie in securing regulatory approvals for key drugs, expanding market presence globally, and accessing nondilutive capital through Priority Review Vouchers, enhancing financial flexibility.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.